First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its recent attendance at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Conference, held October 22-26, 2025, in Boston, ...

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a recent presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany. Starting October 19, 2025, MAIA showcased two e-posters a ...

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 603,769 shares of common stock at a purchase price of $1.22 per share, in a private placement to accredited investors. Each share of common stock is being offered together with a warrant to pur ...

A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of Directors has approved allocating up to 90% of the company's liquid assets into cryptocurrencies, including Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC) for now. Following the news of this move, the stock increased more than 4% intraday. The stock rose ...

公司战略调整 - 公司董事会授权将高达90%的流动资产配置于加密货币 [1][2] - 新的数字资产国库策略专注于顶级加密货币资产 [1] - 初始授权购买和出售的加密货币包括比特币、以太坊和USD Coin [2] 策略执行与管理 - 管理层将定期就加密货币交易、网络安全程序及重大进展向董事会汇报 [2] - 公司计划成立数字资产咨询委员会以支持该策略的执行 [3] - 该策略旨在通过领先的动态加密代币实现投资组合多元化 [3] 战略目标与业务定位 - 策略采用纪律严明且审慎的方法，仅针对最高质量的代币以最小化风险 [3] - 目标是为股东创造和维持价值增长，同时保持充足的营运资金 [3] - 公司是一家临床阶段生物制药公司，专注于开发针对癌症的靶向免疫疗法 [4] - 主要研发项目为Ateganosine，是一种针对端粒酶阳性癌细胞的潜在首创癌症端粒靶向剂 [4]

CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,733,766 shares of common stock at a purchase price of $1.30 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being offered toge ...

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced today that the National Institutes of Health (NIH) has awarded a $2.3 million grant for the expansion of its THIO-101 Ph ...

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more standard-of-care ...

核心观点 - 公司宣布其候选药物ateganosine（THIO）在非小细胞肺癌（NSCLC）治疗中展现出显著疗效和持久性 中位总生存期达17.8个月（95%置信区间下限12.5个月） 并获得FDA快速通道资格认定 [1][3][4] 临床数据与疗效 - THIO-101临床试验显示ateganosine联合cemiplimab治疗三线免疫检查点抑制剂耐药NSCLC患者 可改善无进展生存期（PFS） [1][9] - 中位总生存期（OS）为17.8个月（95% CI下限12.5个月） 表明药物在晚期NSCLC治疗中具有突破潜力 [3] - 治疗方案安全性良好 在经多重预治疗的患者群体中显示出可接受的安全性 [9] 监管进展与资格认定 - FDA授予ateganosine快速通道资格认定 用于治疗非小细胞肺癌 [4] - 公司计划利用快速通道计划的激励措施加速ateganosine的监管审批流程 [4] - 若符合相关标准 药物将有资格获得FDA加速批准和优先审评（审批决定周期缩短至6个月内） [4] 药物机制与研发定位 - Ateganosine为首个靶向端粒的研究性药物 通过诱导端粒酶依赖性端粒DNA修饰、DNA损伤反应和选择性癌细胞死亡发挥作用 [7] - 该药物可激活先天免疫（cGAS/STING）和适应性免疫（T细胞）反应 与PD-(L)1抑制剂序贯治疗可导致晚期癌症模型中出现深度且持久的肿瘤消退 [7] - 目前正开发作为二线或后线治疗 用于对现有检查点抑制剂标准治疗方案进展的NSCLC患者 [7][9] 学术认可与会议展示 - 研究摘要被选入2025年世界肺癌大会（WCLC）海报展示 会议于2025年9月6-9日在巴塞罗那举行 [1][6] - 展示环节为"P1.11 - 转移性非小细胞肺癌免疫治疗" 定于9月7日10:30-12:00进行 [8] - IASLC为全球性多学科组织 致力于消除所有形式的肺癌 其年度会议是分享前沿研究和行业合作的重要平台 [5][6] 公司背景与试验设计 - MAIA Biotechnology为临床阶段生物制药公司 专注于开发靶向免疫疗法 [10] - THIO-101为多中心、开放标签、剂量探索的II期临床试验 旨在评估ateganosine序贯PD-(L)1抑制剂的抗肿瘤活性 [9] - 试验主要目标包括评估安全性、耐受性及以总体缓解率（ORR）为终点的临床疗效 [9]

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, “Cellular Mechanisms of Anti-Cancer Therapies” The manuscript, titled “Periope ...